520880新晋创新药“人气王”，半小时放出7亿成交，资金单日狂揽1．3亿元

Core Viewpoint - The Hong Kong Stock Connect Innovative Drug ETF (520880) is experiencing significant trading activity and price fluctuations, influenced by expectations of interest rate cuts by the Federal Reserve, with a notable increase in market interest and capital inflow [1][3][9]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) opened lower but maintained a slight increase of 0.64% during early trading, reflecting ongoing market interest [1]. - The ETF's trading price has shown a significant premium over its net asset value, with a peak increase of over 8% during trading, prompting the fund manager to issue a risk alert regarding market premiums [3]. - The ETF has seen a substantial capital inflow, with 132 million yuan on a single day and a total of 194 million yuan over two days [3]. Group 2: Index Performance - The Hong Kong Stock Connect Innovative Drug ETF passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug industry, primarily consisting of R&D companies with high concentration in leading stocks [5]. - As of July 29, the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has increased by 107.56% year-to-date, significantly outperforming the Hang Seng Index and the Hang Seng Tech Index by 80.32% and 81.23%, respectively [7][8]. Group 3: Industry Outlook - The innovative drug sector is identified as having clear industry trends and growth potential, with current valuations considered attractive, indicating room for foreign investment in Hong Kong's innovative drug market [9]. - Multiple catalysts, including performance growth and international expansion, are expected to support further strength in the innovative drug sector [9].